News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects [Yahoo! Finance]

RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells [Yahoo! Finance]

RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells

RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement

Top News Decliners

11/4 UPDATE 1-U.S. FDA approves RedHill's bacterial infection treatment [Yahoo! Finance News] -19.7%

3/11 Form 6-K RedHill Biopharma Ltd. For: Mar 11 -17.7%

2/27 RedHill Biopharma to Host Full-Year 2019 Financial Results Conference Call on March 4, 2020 -13.6%

10/11 RedHill Biopharma Announces Full Results from Positive MAP US Phase 3 Study and Supportive Top-Line Results from MAP US2 Open-Label Extension Study with RHB-104 in Crohn’s Disease -13.5%

4/28 RedHill Biopharma Strengthens Coverage for Talicia® with Preferred Brand Position on Prime Therapeutics NetResults™ National Formulary -13.0%

3/9 Form 6-K RedHill Biopharma Ltd. For: Mar 09 -12.6%

7/22 REDHILL BIOPHAR/S (NASDAQ: RDHL) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -12.1%

3/23 RedHill Biopharma to Present at Virtual Life Sciences Investor Forum on March 26 -11.7%

3/17 REDHILL BIOPHAR/S (NASDAQ: RDHL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.75 price target on the stock. -10.5%

2/6 REDHILL BIOPHAR/S (NASDAQ: RDHL) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.3%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}